Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine infusion rate plus low-dose dexmedetomidine for sevoflurane MACBAR in gynecologic surgery
ChiCTR2300072743Phase 4Recruiting
- Sponsor
- Zhongshan Boai Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine, dexmedetomidine and sevoflurane in None (5 arms), sponsored by Zhongshan Boai Hospital. Primary endpoint: Skin incision response. Started Jun 2023; status: recruiting.
02
Drugs
esketaminedexmedetomidinesevoflurane
Beyond the preview
Go deeper on ChiCTR2300072743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072743.